NUTRITION IN CONTEXTNovember 16, 2026
Heart Nutrition
Brief
Heart Health / EVIDENCE GUIDE

L-Arginine After a Heart Attack: Why a Plausible Nitric-Oxide Story Did Not Prove Benefit

Understand L-arginine heart claims through the VINTAGE MI and ARAMI trials, including safety signals, endpoints, and interaction questions.

an HPLC pump
HPLC pump · Beige Alert · CC BY 2.0 · Source · License
THE KEY TAKEAWAY

L-arginine’s nitric-oxide rationale did not translate into proven post-heart-attack benefit, and one small trial raised a serious safety concern.

The mechanism sounds stronger than the clinical evidence

L-arginine is an amino acid used to make nitric oxide, a signaling molecule involved in blood-vessel function. That pathway makes vasodilation claims sound intuitive. Yet increasing a precursor does not guarantee a beneficial clinical response in a person with cardiovascular disease. The body regulates the pathway, and disease, medicines, timing, and dose can alter the result.

Supplement marketing often stops at the mechanism or a short-term blood-flow measurement. Someone recovering from myocardial infarction needs evidence on outcomes and safety in that setting. Randomized post-infarction trials provide a more relevant test than biochemical plausibility, athlete-oriented pump claims, or studies in healthy volunteers.

Images of a spectrophotometer experiment. Equipment from circa 2012.
Spectrophotometer Model 1 · Viv Rolfe · CC BY-SA 4.0 · Source · License

The VINTAGE MI warning

VINTAGE MI randomized 153 adults after a first ST-elevation myocardial infarction to L-arginine or placebo for six months. The supplement did not improve vascular stiffness or ejection fraction. Six participants in the L-arginine group died, compared with none in the placebo group, and the data safety committee stopped the trial early.

The trial was too small to estimate mortality risk precisely, so it cannot define the exact danger for every dose or population. It does establish that a seemingly favorable mechanism is not enough to assume safety after a heart attack. The investigators concluded that L-arginine should not be recommended following acute myocardial infarction.

ARAMI did not establish a clear benefit

The larger ARAMI pilot trial randomized 792 people with ST-elevation myocardial infarction to oral L-arginine or placebo for 30 days on top of routine therapy. Its composite endpoint included cardiovascular death, reinfarction, resuscitation, shock or pulmonary edema, and recurrent ischemia. The result trended favorably but did not reach conventional statistical significance.

A near-significant pilot result is not proof of benefit, especially when another trial raised a safety signal. Different doses, durations, and populations can explain differences, but they do not justify selecting only the favorable study. A meta-analysis of acute-infarction trials likewise did not create a reliable basis for routine supplementation in this high-risk setting.

Other products can hide the same ingredient

L-arginine may appear in pre-workout powders, circulation blends, sexual-health products, and combination amino-acid formulas. The front label may emphasize another ingredient while the supplement facts panel lists several grams of arginine. People with cardiovascular disease should disclose the entire product, not only a standalone arginine bottle.

Potential blood-pressure effects make combinations with nitrates, antihypertensives, or other vasodilating supplements clinically relevant. Products can also add caffeine or stimulants that push in a different direction. A pharmacist can evaluate the full list. A third-party quality seal may support identity or contamination testing, but it does not establish post-heart-attack safety or efficacy.

IMG 1340.jpg
Analytical balance - Thomas Edison National Historical Park - West Orange, New Jersey · Jeff Keyzer from Austin, TX, USA · CC BY-SA 2.0 · Source · License

What to do with a circulation claim

Ask what population was studied, whether participants had established cardiovascular disease, which dose and formulation were used, and whether the endpoint was a temporary blood-flow measure or an event that mattered to patients. A claim that nitric oxide supports circulation should not be allowed to imply recovery, prevention, or survival without direct evidence.

After a heart attack, the priority is the treatment plan developed by the cardiology team, including cardiac rehabilitation and prescribed medicines. Do not add L-arginine or stop therapy based on supplement marketing. The trials are a useful cautionary lesson: biologic plausibility can justify research, but only clinical evidence can show whether an intervention helps, does nothing, or causes harm.

Why small safety trials still matter

A small trial may be unable to prove a mortality difference, yet an imbalance in deaths can still require urgent caution—especially when no meaningful benefit appears. Stopping early protects participants but also leaves wider confidence intervals, so the signal should be described as concerning rather than precisely quantified.

That uncertainty does not justify ignoring the finding. In high-risk settings, the burden belongs on a supplement to demonstrate safety and benefit. Consumers should not be asked to treat absence of a definitive harm estimate as evidence that the product is safe. A careful label warning should reflect the seriousness of the population studied, not merely the popularity of nitric-oxide marketing.

Sources & further reading

  1. L-Arginine Therapy in Acute Myocardial Infarction: VINTAGE MI Trial ↗
  2. Efficacy and Safety of Oral L-Arginine in Acute Myocardial Infarction: ARAMI Trial ↗
  3. Oral L-Arginine Supplementation in Acute Myocardial Infarction: Meta-analysis ↗

This article provides educational information. Ask a qualified clinician or pharmacist about your symptoms, medical conditions, medicines and supplement interactions.

More on Heart Health →